These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16838335)

  • 1. Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature.
    Streiff MB; Segal JB; Tamariz LJ; Jenckes MW; Bolger DT; Eng J; Krishnan JA; Bass EB
    Am J Hematol; 2006 Sep; 81(9):684-91. PubMed ID: 16838335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
    Wang W; Su Y; Wu C; Sun Y; Dai N; Chen W; Zhang J; Xu Y; Brindis RG; Xu D; Li J
    BMC Cardiovasc Disord; 2020 Feb; 20(1):53. PubMed ID: 32013892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
    Middeldorp S; Prins MH; Hutten BA
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD001367. PubMed ID: 25092359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case-control study.
    Martinez C; Katholing A; Folkerts K; Cohen AT
    J Thromb Haemost; 2016 Jul; 14(7):1374-83. PubMed ID: 27079164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII.
    Eischer L; Gartner V; Schulman S; Kyrle PA; Eichinger S;
    Ann Hematol; 2009 May; 88(5):485-90. PubMed ID: 18931845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
    Hutten BA; Prins MH
    Cochrane Database Syst Rev; 2000; (3):CD001367. PubMed ID: 10908494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thirteen-year trend in the persistence with vitamin K antagonists for venous thromboembolism in the UK: a cohort study.
    Martinez C; Katholing A; Folkerts K; Rietbrock S
    Curr Med Res Opin; 2018 Nov; 34(11):1985-1990. PubMed ID: 29798688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
    Louzada ML; Majeed H; Wells PS
    Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandalà M; Papaldo P; Fabi A; Ciccarese M; Cuppone F; Cecere FL; Nuzzo C; Terzoli E; Cognetti F
    Chest; 2006 Dec; 130(6):1808-16. PubMed ID: 17167001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study.
    Eischer L; Kammer M; Traby L; Kyrle PA; Eichinger S
    J Thromb Haemost; 2017 Jul; 15(7):1368-1374. PubMed ID: 28407356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.
    Siragusa S; Malato A; Saccullo G; Iorio A; Di Ianni M; Caracciolo C; Coco LL; Raso S; Santoro M; Guarneri FP; Tuttolomondo A; Pinto A; Pepe I; Casuccio A; Abbadessa V; Licata G; Battista Rini G; Mariani G; Di Fede G
    Am J Hematol; 2011 Nov; 86(11):914-7. PubMed ID: 21953853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.
    Shrivastava S; Ridker PM; Glynn RJ; Goldhaber SZ; Moll S; Bounameaux H; Bauer KA; Kessler CM; Cushman M
    J Thromb Haemost; 2006 Jun; 4(6):1208-14. PubMed ID: 16706961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-Dimer Levels and Vitamin K Antagonist Therapy in Deep Vein Thrombosis of the Legs.
    Park JK; Koo do H; Yoon DH; Lee JN
    Ann Vasc Surg; 2016 Jul; 34():119-34. PubMed ID: 27177705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
    Hutten BA; Prins MH
    Cochrane Database Syst Rev; 2006 Jan; (1):CD001367. PubMed ID: 16437432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
    Kyrle PA; Kammer M; Eischer L; Weltermann A; Minar E; Hirschl M; Heinze G; Eichinger S
    J Thromb Haemost; 2016 Dec; 14(12):2402-2409. PubMed ID: 27696701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients.
    Mearns ES; Kohn CG; Song JS; Hawthorne J; Meng J; White CM; Raut MK; Schein JR; Coleman CI
    Thromb Res; 2014 Aug; 134(2):310-9. PubMed ID: 24935672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.